This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Littrell, K. H. Search for Related Content Social Bookmarking                   What's this?

Beyond Compliance: Evaluating Antipsychotic Efficacy

Promedica, Inc., 3758 Lavista Rd., Suite 100, Tucker, GA 30095.

Over the past 40 years, clinicians have refined the pharmacologic treatment of patients with schizophrenia. Within the past several years, the introduction of two new antipsychotic medications, clozapine and risperidone, has considerably improved the quality of life of patients with schizophrenia. The availability of these newer antipsychotic drugs raises several questions: how wel patients will comply with these medications, how to accurately assess efficacy, and how to switch from one antipsychotic agent to another. Each of these issues is addressed in this article.

Journal of the American Psychiatric Nurses Association, Vol. 2, No. 5, 186-190 (1996)
DOI: 10.1177/107839039600200512


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?